2
Key Points
` Consistent with the ACR's 2019 JIA guidelines, these recommendations
are for persons already diagnosed with juvenile idiopathic arthritis (JIA).
` Aside from poor prognostic features specified within the
recommendations themselves (e.g., specific joints for oligoarthritis,
macrophage activation syndrome [MAS]), extra-articular coexisting
conditions that would influence disease management, such as uveitis,
psoriasis or inflammatory bowel disease, are not addressed within these
guidelines.
` Recommendations are intended to be used by all clinicians caring for
persons with JIA and assume that patients do not have contraindications
to the recommended pharmacologic treatments.
` Longer-term glucocorticoid therapy in childhood is not appropriate
because of its effects on bone health and growth. Thus, wherever
glucocorticoids are suggested, recommended treatment should be
limited to the lowest effective dose for the shortest duration possible.
` Shared decision-making with families and patients is important when
considering treatment options.
